These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24077981)

  • 21. Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
    Schønnemann KR; Jensen HA; Yilmaz M; Jensen BY; Larsen O; Pfeiffer P
    Br J Cancer; 2008 Sep; 99(6):858-61. PubMed ID: 19238627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Kim TW; Kang YK; Ahn JH; Chang HM; Yook JH; Oh ST; Kim BS; Lee JS
    Ann Oncol; 2002 Dec; 13(12):1893-8. PubMed ID: 12453857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
    Liu Y; Ma T; Ye ZB; Zhang J; Zhu ZG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Mar; 13(3):177-80. PubMed ID: 20336533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
    Uronis HE; Bendell JC; Altomare I; Blobe GC; Hsu SD; Morse MA; Pang H; Zafar SY; Conkling P; Favaro J; Arrowood CC; Cushman SM; Meadows KL; Brady JC; Nixon AB; Hurwitz HI
    Oncologist; 2013; 18(3):271-2. PubMed ID: 23485624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
    Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
    Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
    Rivera F; Massutí B; Salcedo M; Sastre J; Martínez Galán J; Valladares-Ayerbes M; Serrano R; García de Paredes ML; Manzano JL; Galán M; Alsina M; Yuste Izquierdo AL; López C; Díaz-Rubio E; Conde V; Reboredo M; Cano MT; Pachón V; Aranda E
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):319-24. PubMed ID: 25491381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
    Anter AH; Abdel-Latif RM
    Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
    Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
    Liu C; Sun Q; Hang X; Zhong B; Wang D
    Anticancer Drugs; 2008 Sep; 19(8):825-31. PubMed ID: 18690095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
    Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
    Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
    J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
    Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
    Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
    Borner MM; Dietrich D; Stupp R; Morant R; Honegger H; Wernli M; Herrmann R; Pestalozzi BC; Saletti P; Hanselmann S; Müller S; Brauchli P; Castiglione-Gertsch M; Goldhirsch A; Roth AD
    J Clin Oncol; 2002 Apr; 20(7):1759-66. PubMed ID: 11919232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
    Sumpter K; Harper-Wynne C; Cunningham D; Rao S; Tebbutt N; Norman AR; Ward C; Iveson T; Nicolson M; Hickish T; Hill M; Oates J
    Br J Cancer; 2005 Jun; 92(11):1976-83. PubMed ID: 15928658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
    Waddell T; Chau I; Cunningham D; Gonzalez D; Okines AF; Okines C; Wotherspoon A; Saffery C; Middleton G; Wadsley J; Ferry D; Mansoor W; Crosby T; Coxon F; Smith D; Waters J; Iveson T; Falk S; Slater S; Peckitt C; Barbachano Y
    Lancet Oncol; 2013 May; 14(6):481-9. PubMed ID: 23594787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Bang YJ; Kim YW; Yang HK; Chung HC; Park YK; Lee KH; Lee KW; Kim YH; Noh SI; Cho JY; Mok YJ; Kim YH; Ji J; Yeh TS; Button P; Sirzén F; Noh SH;
    Lancet; 2012 Jan; 379(9813):315-21. PubMed ID: 22226517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
    Sun W; Powell M; O'Dwyer PJ; Catalano P; Ansari RH; Benson AB
    J Clin Oncol; 2010 Jun; 28(18):2947-51. PubMed ID: 20458043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.